Drug Profile
Research programme: heart failure therapeutic - Bio-Medisinsk Innovasjon/GlaxoSmithKline
Latest Information Update: 28 Mar 2018
Price :
$50
*
At a glance
- Originator Bio-Medisinsk Innovasjon; GlaxoSmithKline
- Developer Bio-Medisinsk Innovasjon; GSK
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Heart failure
Most Recent Events
- 28 Mar 2018 No recent reports of development identified for research development in Heart-failure in Norway
- 28 Mar 2018 No recent reports of development identified for research development in Heart-failure in United Kingdom